Marijuana
Spinal Cord Injury
Khon Kaen UniversityPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Spinal Cord Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxcarbamezapine Ju Seok Ryu | Phase 4 | BB |
Xeomin® Catholic University of Korea Saint Paul's Hospital | Phase 4 | B |
Tizanidine Elan Pharmaceuticals | Phase 3 | B |
TIRILAZAD National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | B |
Dextromethorphan Brigham and Women's Hospital | Phase 2 | B |
View all 19 →
Same molecule, other indications
Marijuana is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →